- Home
- EVMN vs GUG Comparison
EVMN vs GUG Comparison
Compare EVMN & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVMN | GUG |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.7M | 509.2M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVMN | GUG |
|---|---|---|
| Price | $9.60 | $14.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $43.88 | N/A |
| AVG Volume (30 Days) | ★ 589.8K | 98.1K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 85.71 | N/A |
| 52 Week Low | $9.20 | $14.22 |
| 52 Week High | $33.20 | $16.46 |
Technical Indicators
Market Signals| Indicator | EVMN | GUG |
|---|---|---|
| Relative Strength Index (RSI) | 32.30 | 33.95 |
| Support Level | N/A | $14.22 |
| Resistance Level | $13.35 | $16.09 |
| Average True Range (ATR) | 0.66 | 0.23 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 10.24 | 15.38 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.